Search results (236)
« Back to PublicationsComplement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Mellors J. et al, (2025), Nat Commun, 16
MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-α chain.
Dolton G. et al, (2025), J Clin Invest, 135
Footprints of innate immune activity during HIV-1 reservoir cell evolution in early-treated infection.
Sun W. et al, (2024), J Exp Med, 221
Impact of antiretroviral therapy during primary HIV infection on T-cell immunity after treatment interruption.
Tipoe T. et al, (2024), Eur J Immunol, 54
Learning patterns of HIV-1 resistance to broadly neutralizing antibodies with reduced subtype bias using multi-task learning.
Igiraneza AB. et al, (2024), PLoS Comput Biol, 20
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery.
Ali M. et al, (2024), Clin Exp Immunol, 218, 78 - 92
Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial.
Alagaratnam J. et al, (2024), J Virus Erad, 10
Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery.
Thornhill JP. et al, (2024), AIDS, 38, 679 - 688
Prevalence of resistance-associated viral variants to the HIV-specific broadly neutralising antibody 10-1074 in a UK bNAb-naïve population.
Zacharopoulou P. et al, (2024), Front Immunol, 15
Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.
Nel C. and Frater J., (2024), Front Immunol, 15